For example, patients with advanced non-small cell lung cancer (NSCLC) that harbor mutations that activate epidermal growth factor receptor (EGFR) can be treated with EGFR-tyrosine kinase inhibitors (TKIs) such as gefitinib. Here, EGFR is linked to non-small cell lung carcinoma.